Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 250

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients

Open access
Besarab, Anatole, Chernyavskaya, Elena, Motylev, Igor, Shutov, Evgeny, Kumbar, Lalathaksha M., Gurevich, Konstantin, Chan, Daniel Tak Mao, Leong, Robert, Poole, Lona, Zhong, Ming, Saikali, Khalil G., Franco, Marietta, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B. · 2016 · Journal of the American Society of Nephrology

Abstract

Safety concerns with erythropoietin analogues and intravenous (IV) iron for treatment of anemia in CKD necessitate development of safer therapies. Roxadustat (FG-4592) is an orally bioavailable hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that promotes coordinated erythropoiesis through HIF-mediated transcription. We performed an open-label, randomized hemoglobin (Hb) correction study in anemic (Hb≤10.0 g/dl) patients incident to hemodialysis (HD) or peritoneal dialysis (PD). Sixty patients received no iron, oral iron, or IV iron while treated with roxadustat for 12 weeks. Mean±SD baseline Hb was 8.3±1.0 g/dl in enrolled patients. Roxadustat at titrated doses increased mean Hb by ≥2.0 g/dl within 7 weeks regardless of baseline iron repletion status, C-reactive protein level, iron regimen, or dialysis modality. Mean±SEM maximal change in Hb from baseline (ΔHb(max)), the primary endpoint, was 3.1±0.2 g/dl over 12 weeks in efficacy-evaluable patients (n=55). In groups receiving oral or IV iron, ΔHb(max) was similar and larger than in the no-iron group. Hb response (increase in Hb of ≥1.0 g/dl from baseline) was achieved in 96% of efficacy-evaluable patients. Mean serum hepcidin decreased significantly 4 weeks into study: by 80% in HD patients receiving no iron (n=22), 52% in HD and PD patients receiving oral iron (n=21), and 41% in HD patients receiving IV iron (n=9). In summary, roxadustat was well tolerated and corrected anemia in incident HD and PD patients, regardless of baseline iron repletion status or C-reactive protein level and with oral or IV iron supplementation; it also reduced serum hepcidin levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2015030241

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 250

Metadata

Authors
Besarab, A., Chernyavskaya, E., Motylev, I., Shutov, E., Kumbar, L. M., Gurevich, K., Chan, D. T. M., Leong, R., Poole, L., Zhong, M., Saikali, K. G., Franco, M., Hemmerich, S., Yu, K.-H. P., & Neff, T. B.
Venue
Journal of the American Society of Nephrology
Published
2016-04
Volume
27
Issue
4
Pages
1225-1233
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2178101235
Cited by
250
References
6
FWCI
19.45
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. https://app.cochat.ai/papers/10.1681/asn.2015030241
The paper
Besarab, A., Chernyavskaya, E., Motylev, I., Shutov, E., Kumbar, L. M., Gurevich, K., Chan, D. T. M., Leong, R., Poole, L., Zhong, M., Saikali, K. G., Franco, M., Hemmerich, S., Yu, K.-H. P., & Neff, T. B. (2016). Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2015030241

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.